Featured Studies Results
Research Study on the Genetics of Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/317/research-study-on-the-genetics-of-breast-cancer
Clinicaltrials.gov identifier:
NCT06773897 (https://clinicaltrials.gov/show/NCT06773897)
Surveys, Registries, Interviews
A registry for anyone aged 18 and older who lives in the United States
Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T
https://www.facingourrisk.org/research-clinical-trials/study/364/treating-advanced-or-metastatic-breast-cancer-with-a-type-of-immunotherapy-called-car-t
Clinicaltrials.gov identifier:
NCT06878248 (https://clinicaltrials.gov/show/NCT06878248)
Treatment
Phase 1 treatment study for people with advanced solid tumors
Study of a New Drug, Sacituzumab Tirumotecan, Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer (TroFuse-011)
https://www.facingourrisk.org/research-clinical-trials/study/359/study-of-a-new-drug-sacituzumab-tirumotecan-given-alone-or-in-combination-with-an-immunotherapy-for-people-with-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT06841354 (https://clinicaltrials.gov/show/NCT06841354)
Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer
Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab
https://www.facingourrisk.org/research-clinical-trials/study/362/testing-an-immunotherapy-drug-nivolumab-with-or-without-the-immunotherapy-drug-ipilimumab-for-recurrent-dmmr-endometrial-cancer
Clinicaltrials.gov identifier:
NCT05112601 (https://clinicaltrials.gov/show/NCT05112601)
Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
https://www.facingourrisk.org/research-clinical-trials/study/360/the-prostate-cancer-genetic-risk-and-equitable-screening-study-progress
Clinicaltrials.gov identifier:
NCT05926102 (https://clinicaltrials.gov/show/NCT05926102)
Prevention
Prostate cancer screening study for male US veterans age 55–69
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
https://www.facingourrisk.org/research-clinical-trials/study/356/treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies
Clinicaltrials.gov identifier:
NCT06974110 (https://clinicaltrials.gov/show/NCT06974110)
Treatment
Treatment study for people with advanced or metastatic cancers
Study of an Investigational Drug, E7386 Plus Lenvatinib in People with Endometrial Cancer after Chemotherapy and Immunotherapy
https://www.facingourrisk.org/research-clinical-trials/study/355/study-of-a-new-drug-e7386-in-combination-with-lenvatinib-in-people-with-previously-treated-endometrial-cancer
Clinicaltrials.gov identifier:
NCT04008797 (https://clinicaltrials.gov/show/NCT04008797)
Treatment
Treatment study for people with previously treated endometrial cancer
Using a Shorter Type of MRI as a Screening Tool for People at High Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/353/using-biparametric-magnetic-resonance-imaging-mri-as-a-screening-tool-for-those-at-high-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT05384535 (https://clinicaltrials.gov/show/NCT05384535)
Prevention
Screening for people at high risk for prostate cancer
NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/314/neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer
Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)
Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations
Treating Advanced Breast Cancer or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)
https://www.facingourrisk.org/research-clinical-trials/study/363/testing-a-new-drug-zen003694-with-chemotherapy-abemaciclib-for-people-with-advanced-or-inoperable-breast-cancer-and-other-solid-tumors
Clinicaltrials.gov identifier:
NCT05372640 (https://clinicaltrials.gov/show/NCT05372640)
Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors
Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib
Clinicaltrials.gov identifier:
NCT06545942 (https://clinicaltrials.gov/show/NCT06545942)
Treatment
Treatment study for people with advanced or metastatic cancers
Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling
https://www.facingourrisk.org/research-clinical-trials/study/321/pfizer-clinical-trials-for-metastatic-prostate-cancer-are-now-enrolling
Treatment
Men aged 18 years or older with metastatic prostate cancer
Learning about the Needs of Autistic People Related to Breast Cancer Screening and Testing
https://www.facingourrisk.org/research-clinical-trials/study/341/learning-about-the-needs-of-autistic-people-related-to-breast-cancer-screening-and-testing
Surveys, Registries, Interviews
Online survey for autistic people with or at high risk for breast cancer
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for MMR-D or MSI-H Stage IIB - III Colon Cancer
https://www.facingourrisk.org/research-clinical-trials/study/358/post-surgery-immunotherapy-toripalimab-for-mmr-d-msi-h-stage-iib-iii-colon-cancer
Clinicaltrials.gov identifier:
NCT07140679 (https://clinicaltrials.gov/show/NCT07140679)
Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer
Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer in People with a BRCA Mutation or a Biomarker Called HRD
https://www.facingourrisk.org/research-clinical-trials/study/361/testing-olaparib-for-one-or-two-years-with-or-without-bevacizumab-to-treat-ovarian-cancer-with-a-brca-mutation-or-a-biomarker-called-hrd
Clinicaltrials.gov identifier:
NCT06580314 (https://clinicaltrials.gov/show/NCT06580314)
Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)
https://www.facingourrisk.org/research-clinical-trials/study/347/testing-higher-dose-radiation-therapy-for-locally-advanced-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT06958328 (https://clinicaltrials.gov/show/NCT06958328)
Treatment
Radiation treatment study for people with locally advanced pancreatic cancer
Pancreatic Cancer Screening Study for People with ATM, BRCA1, BRCA2 or PALB2 Mutations
https://www.facingourrisk.org/research-clinical-trials/study/330/screening-study-for-pancreatic-cancer
Clinicaltrials.gov identifier:
NCT05058846 (https://clinicaltrials.gov/show/NCT05058846)
Prevention
Pancreatic cancer screening study for people with ATM, BRCA1, BRCA2 or PALB2 mutations
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.